Abbott closes Kos acquisition
Executive Summary
Abbott completes its $3.7 billion cash purchase of Kos Pharmaceuticals in just thirty business days, CFO Thomas Freyman announces during the JP Morgan Healthcare Conference Jan. 9. The deal, proposed by Abbott in early November, will help diversify the firm's existing cardiovascular franchise, and could also expand its pipeline into respiratory diseases (1"The Pink Sheet" Nov. 13, 2006, p. 13)...
You may also be interested in...
Abbott Expands Pharmaceutical Pipeline With $3.7 Bil Kos Acquisition
Abbott's proposed $3.7 bil. acquisition of Kos Pharmaceuticals will help diversify Abbott's existing cardiovascular franchise, and could also expand its pipeline into respiratory diseases
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.